
|Articles|September 29, 2022
Achieving High Yield, Versatility, and Scalability for Adherent Cell Culture with Circulation/Perfusion Systems
Author(s)Corning Life Sciences
With the ever-growing demand for vaccines and advanced therapy products, cell culture platforms are challenged to provide cost-effective, high-yield production that can easily transition from process development through large-scale manufacturing. Ann Rossi Bilodeau, Ph.D. from Corning Life Sciences discusses what the Corning® CellCube® has to offer for the end user.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
2
FAQ: What You Need to Know About How Industry is Tackling CGT Bottlenecks
3
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
4
Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration
5
